CreativeOne Wealth LLC Has $2.73 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

CreativeOne Wealth LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.7% in the 3rd quarter, Holdings Channel reports. The firm owned 5,620 shares of the medical research company’s stock after selling 2,158 shares during the period. CreativeOne Wealth LLC’s holdings in Thermo Fisher Scientific were worth $2,726,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Natixis Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 18.7% in the 3rd quarter. Natixis Advisors LLC now owns 482,430 shares of the medical research company’s stock valued at $233,987,000 after purchasing an additional 75,993 shares during the last quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its stake in Thermo Fisher Scientific by 17.1% in the third quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 126,612 shares of the medical research company’s stock valued at $61,409,000 after buying an additional 18,447 shares in the last quarter. Rhenman & Partners Asset Management AB grew its position in Thermo Fisher Scientific by 169.7% in the third quarter. Rhenman & Partners Asset Management AB now owns 30,040 shares of the medical research company’s stock valued at $14,570,000 after acquiring an additional 18,900 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC raised its stake in Thermo Fisher Scientific by 15.7% during the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 2,141,863 shares of the medical research company’s stock worth $1,038,847,000 after acquiring an additional 290,558 shares in the last quarter. Finally, Munich Reinsurance Co Stock Corp in Munich acquired a new position in Thermo Fisher Scientific during the third quarter worth about $18,855,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research analyst reports. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target on the stock in a research note on Sunday, December 7th. Citigroup increased their price objective on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Evercore reaffirmed an “outperform” rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Stifel Nicolaus upped their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Finally, Morgan Stanley raised their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $633.68.

Thermo Fisher Scientific Trading Up 1.7%

TMO opened at $510.28 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company’s 50 day moving average price is $565.80 and its two-hundred day moving average price is $549.24. The firm has a market capitalization of $189.56 billion, a price-to-earnings ratio of 28.76, a PEG ratio of 2.89 and a beta of 0.96.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter last year, the firm earned $6.10 earnings per share. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be given a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date is Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.70%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.